A cell surface antigen on human parathyroid cells was identified by monoclonal antibodies. The antigen, called parathyroid antigen (PTA), is found on both of two major polypeptides (190 kDa and 160 kDa) apparently associated exclusively with parathyroid cells. To determine whether PTA was a suitable target for in vivo imaging, 125I-labeled anti-PTA was injected into nude mice bearing human parathyroid xenografts. IgG1 anti-PTA antibody showed excellent radiolocalization of the grafts, whereas IgM anti-PTA, containing the same variable domains as the IgG1 antibody, showed little specific binding. These results suggest that antibody isotype is an important parameter for the in vivo immunoscintigraphy of specific cellular antigens.
Although localization of specific tissues with radiolabeled antibodies has been attempted for many years (1), it was not until the advent of hybridoma technology that abundant quantities of monoclonal antibodies of high specificity and purity became available. Numerous investigators used monoclonal antibodies developed against human tumor cells to radioimage tumor xenografts, usually in nude mouse model systems (2) (3) (4) (5) (6) (7) (8) (9) . However, most of these studies focused on poorly defined and often nonspecific tumor-associated antigens. Additionally, the radioimaging studies utilizing large, rapidly growing neoplasms were complicated by the increased uptake of nonspecific antibody (10) and the release of antigen into the blood. Thus, little knowledge has been gained regarding the important variables influencing cellular localization in vivo, such as antigen density and stability and antibody affinity and class (11, 12) .
We have developed monoclonal antibodies apparently specific for a unique human parathyroid cell membrane antigen (PTA). By isolating variant hybridoma cells, socalled switch variants (13) , we have generated anti-PTA antibodies of IgG1 and IgM isotypes with identical variable domains. Only IgG1 antibodies localize to human parathyroid xenografts in nude mice, apparently because of differences in the diffusion of antibodies across capillary endothelial cells. (20) . In certain animals, 5 x 106 cells of a control human breast carcinoma line, (21), were transplanted into the flank contralateral to the parathyroid implants. These grafts were allowed at least 3 weeks to develop vascularization before in vivo experiments were conducted.
In Vivo Localization Studies. In these experiments, 200 ,g of purified BB5-M or BB5-G1 was labeled with 300 ,uCi (1 Ci = 37 GBq) of Na'251 or Na131I (Amersham) by using the Iodogen technique (22) . Immunoreactivity of the radiolabeled antibody was documented by cell-binding assays on dispersed parathyroid cells (data not shown). Radiolabeled antibody was passed through a 0.2-gm filter and injected into the tail veins of mice. The animals were sacrificed at specific times after injection of the antibodies. The parathyroid grafts and other tissue samples were removed and weighed, and radioactivity was determined in a y scintillation counter. The values for percent injected dose/g of tissue (% ID/g) were calculated by comparing the amount of radioactivity in each tissue with the amount injected into the animal.
In one series of experiments, the grafts were excised and immediately fixed in 10% Formalin. These grafts were sectioned and autoradiographs were prepared by dipping the sections into NTB-2 emulsion (Kodak).
RESULTS
Specificity of Monoclonal Anti-PTA Antibody. The monoclonal antibody BB5-M bound to human parathyroid tissue, as determined by bright speckled staining (Fig. LA) . The antibody cross-reacted strongly with parathyroid tissue of rhesus and pigtail monkeys and mongrel dogs, but it reacted weakly with bovine parathyroid cells and not at all with rabbit or rat parathyroid glands. The specificity of BB5-M is shown in a section of intrathyroidal monkey parathyroid tissue in which parathyroid but not thyroid cells are stained (Fig. 1B) . BB5-M was also screened against a variety of human, monkey, and canine tissues ( (Fig. 2A) . The minor polypeptide, however, was not present in two of nine cellular preparations tested. The molecular masses of the molecules were approximately 20 kDa less under reducing conditions. Washing the immunoprecipitates with 0.1% NaDodSO4/0.65 M NaCl before NaDodSO4/PAGE analysis did not change the electrophoretic pattern.
To determine which of the polypeptides expressed the BB5 epitope, a cellular protein extract obtained from fresh undigested parathyroid tissue was analyzed by immunoblotting before and after reduction. BB5-M bound to the same two high molecular weight molecules as demonstrated by cell surface labeling and immunoprecipitation (Fig. 2B ). Therefore, both polypeptides express the same or similar epitopes. In addition, cellular protein extracts were obtained from fresh tonsil, thyroid, pancreas, lymph node, spleen, and isolated pancreatic islet cell specimens and analyzed by immunoblotting. There was no evidence for BB5-M binding to other cellular components besides those obtained from parathyroid.
In (Fig. 3) . These cells were cloned and the IgG1 antibody produced by the variant, BB5-G1, bound parathyroid tissue and immunoprecipitated the same molecules as BB5-M.
To determine whether BB5-G1 could bind to human parathyroid tissue in vivo, nude mice bearing xenografts of human parathyroid or other tissues were injected with 125I-labeled BB5-G1 (I251-BB5-Gl). In an initial time course study, the % ID/g in the parathyroid grafts increased linearly such that by day 7, a level of 28% ID/g was obtained (Fig.  4A) . In contrast, the % ID/g in the blood was highest at day 1, after which it steadily declined. The % ID/g in all other tissues tested remained relatively low (5% or less) throughout the entire experiment.
Since 125I-BB5-Gl clearly bound to human parathyroid tissue in vivo, the effect of dose on parathyroid uptake was examined. A dose of50 ,g per mouse gave the highest % ID/g of parathyroid tissue (Fig. 4B) ; increasing the dose to 150 ,g per mouse resulted in a decrease in the % ID/g. Although not statistically significant (P = 0.053), this result is consistent with saturability ofthe target antigen. The levels ofradiolabel in the blood and the other tissues were not significantly different between the three groups of mice. In contrast to the efficient binding of 1251-BB5-Gl to parathyroid cells in vivo, similar doses of 1251-BB5-M showed little specific binding (Fig. 5) . The small amount of IgM antibody binding to parathyroid on day 1 was lost by day 4, whereas the IgG1 antibody continued to bind avidly.
To assess the precise localization of the antibody, autoradiographs were made oftissue sections ofthe parathyroid and control grafts. In the mice receiving 125I-BB5-G1, dense collections of silver grains were present over the clusters of 25I-BB5-G1 was injected into three groups of mice (three mice per group) at the following dosages: A, 15 ,.tg; B, 50 ,ug; C, 150 ,g. The mice were sacrificed on day 4. parathyroid cells (Fig. 6 A and B) . The silver grains were concentrated more around the peripheral, well-vascularized, areas of the grafts than over the fibrotic central portions. The mice that received 1251-BB5-M showed no localization of silver grains over the parathyroid cells (Fig. 6 C and D) . In 
DISCUSSION
Monoclonal antibody BB5 recognized a parathyroid-associated antigen present on all 20 normal, hyperplastic, and neoplastic parathyroid specimens tested. There was no evidence from immunohistological or biochemical studies for any binding to other tissues. The antigen bound by BB5, which we call PTA, is most likely comprised of a single polypeptide chain of two or three distinct molecular weights as shown on NaDodSO4/PAGE and immunoblotting. Since the two or three forms are seen on these blots, the antigenic determinant is present on molecules, favoring the hypothesis that these bands represent different levels of cellular or extracellular processing of the same molecule. Another possibility, although less likely, is that a unique component, possibly a polysaccharide, is shared by the two or three polypeptides. The slight shift in size under reducing conditions perhaps indicates intrachain disulfide bond(s At least a portion of the antigen is present on the parathyroid cell surface. We were surprised, therefore, that BB5-M showed little tendency to bind to dog parathyroid glands in situ or human parathyroid xenografts in nude mice. There have been isolated reports of localization of specific cellular antigens with radiolabeled IgM monoclonal antibodies (7, 8) .
However, other investigators have demonstrated lack of uptake of IgM in tumor localization studies in vivo. Pimm and Baldwin (26) showed lack of localization of an IgM monoclonal antibody that recognized a determinant on human colon carcinoma cells. Midoux et al. (27) compared an IgM with an IgG2a monoclonal antibody for in vivo localization in C57BL/6 mice bearing Lewis lung carcinomas. They found that tumor-to-tissue ratios at 48 hr were higher with the IgM than the IgG; however, the % ID in the tumor was 5% for the IgG, compared to only 0.5% for the IgM. It is difficult to interpret these results since this study compared two different antibodies to unknown epitopes on the tumor cells.
Since parathyroid glands are highly vascularized by capillaries with typical fenestrated endothelial junctions (28) and IgM is known to diffuse slowly out of the vascular bed (29) , it is possible that only small amounts BB5-M reached the parathyroid cell surface. To test this hypothesis, we isolated an IgG1 switch variant of BB5-M, using the approach of Dangl and Herzenberg (18) , who showed that hybridoma cell lines often express rare cells producing immunoglobulin of different heavy chain class than the parent, but with identical light chains and heavy chain variable domains. This permitted us to compare the localizing capacities of two antibodies that differed only in heavy chain isotype. The results were clear. The IgG1 antibody bound specifically to human parathyroid xenografts for at least 7 days, with an efficiency of 10-28% of the ID/g of tissue. The IgM antibody showed binding of 3% or less of the ID/g, the same as control tissues. Autoradiographs of parathyroid tissue from mice that received radiolabeled BB5-G1 confirmed that this binding was specific for the parathyroid cells and was most concentrated around the periphery of the graft. Since the grafts are dependent on a parasitic blood supply until neovascularization occurs, they often contain some central areas of necrosis and fibrosis, with the clusters of viable parathyroid cells located peripherally. A similar histological pattern has been noted in other radiolocalization studies in tumor models (4, 30) .
In summary, we have described an antigen on human parathyroid tissue that can be recognized and bound in vivo by a specific monoclonal antibody. Although we have shown that IgG1 antibodies are superior to IgM for in vivo localization in nude mice, it is possible that other isotypes will be even better. Other investigators have demonstrated functional differences between the IgG subclass switch variants (11, 12, 31) . Therefore, it should be useful to isolate other switch variants. Furthermore, we expect that differences in the localizing capacities of the various mouse isotypes will be found as we explore imaging of human parathyroids in situ. It is clear from preliminary results described here that careful attention to antibody class will be important in radioimaging, and perhaps in other applications of monoclonal antibodies in vivo.
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